BACKGROUND & AIMS:
Bowel healing is an important goal of therapy for patients with Crohn's disease (CD). Although there have been many studies of mucosal healing, transmural healing (ie, in the bowel wall) has not been investigated in children. We analyzed data from the ImageKids study to determine associations among mucosal, transmural healing and levels of calprotectin and C-reactive protein in children with CD.
METHODS:
We collected data from a multi-center study designed to develop 2 magnetic resonance enterography (MRE)-based measures for children with CD (6-18 years old). In our analysis of 151 children (mean age, 14.2 -2.4 years), all patients underwent MRE and a complete ileocolonoscopic evaluation; fecal levels of calprotectin and blood levels of C-reactive protein were measured. Mucosal healing was defined as simple endoscopic severity index in CD score below 3, transmural healing as an MRE visual analogue score below 20 mm, and deep healing as a combination of transmural and mucosal healing.
RESULTS:
We identified mucosal healing with transmural inflammation in 9 children (6%), transmural healing with mucosal inflammation in 38 children (25%), deep healing in 21 children (14%), and mucosal and transmural inflammation in 83 children (55%). The median level of calprotectin was lowest in children with deep healing (mean level, 10 mg/g; interquartile range, 10-190 mg/g), followed by children with either transmural or mucosal inflammation, and highest in children with mucosal and transmural inflammation (810 mg/g; interquartile range, 539-1737 mg/g) (P < .001). Fecal level of calprotectin identified children with deep healing with an area under the receiver operating characteristic curve value of 0.93 (95% CI, 0.89-0.98); level of C-reactive protein identified children with deep healing with an area under the receiver operating characteristic curve value of 0.81 (95% CI, 0.71-0.9). A calprotectin cutoff value of 100 mg/g identified children with deep healing with 71% sensitivity and 92% specificity; a cutoff value of 300 mg/g identified children with mucosal healing with 80% sensitivity and 81% specificity.
CONCLUSIONS:
In a prospective study of children with CD, we found that one-third have healing in only the mucosa or the bowel wall (not both). Levels of fecal calprotectin below 300 mg/identify children with mucosal healing, but a lower cutoff value (below 100 mg/g) is needed to identify children with deep healing. Clinicaltrials.gov no: NCT01881490.
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N umerous studies have found that achieving mucosal healing in Crohn's disease (CD) is associated with lower risk for future relapses, hospitalizations, and surgical interventions. [1] [2] [3] [4] [5] [6] However, the degree of intestinal inflammation is poorly correlated with clinical symptoms. 7, 8 In children, the correlation of the weighted Pediatric Crohn's Disease Activity Index (wPCDAI) and the Pediatric Crohn's Disease Activity Index (PCDAI) with the Simple Endoscopic Severity Index in Crohn's Disease (SESCD) does not surpass 0. 42-0.45. 9 Repeated ileocolonoscopic evaluation of the mucosa is therefore increasingly used in clinical practice, with varying thresholds of the SESCD to define mucosal healing, frequently using SESCD <3, or absence of ulcerations. [10] [11] [12] [13] However, endoscopy can neither evaluate the deep layers of the intestinal wall nor visualize most of the small bowel. These shortcomings can be addressed by concurrent use of magnetic resonance enterography (MRE), [14] [15] [16] which can utilize the Magnetic Resonance Index of Activity (MaRIA) score in adults, [16] [17] [18] [19] but also by a radiologist's global assessment (RGA) of MRE inflammation. [20] [21] [22] The increasing use of MRE in CD has introduced a new challenge: how to define healing by imaging and how to interpret discrepancies between mucosal healing and persistence of transmural inflammation and, vice versa, between mucosal inflammation and transmural healing. Although mucosal healing has been studied in depth, achieving transmural healing, which includes the deeper layers of the bowel, has infrequently been investigated, particularly in children.
We aimed to explore the association between mucosal healing (assessed by ileocolonoscopy), transmural healing (assessed by concurrent MRE), calprotectin, and C-reactive protein (CRP) in pediatric CD, using prospectively collected data.
Methods
This study was conducted on a cohort of patients from the multicenter ImageKids study (clinicaltrials.gov NCT01881490), designed to develop 2 MRE-based measures for pediatric CD. The Pediatric Inflammatory Crohn's Disease MRE Index (PICMI) will measure inflammation, and the Pediatric MRE Damage Index in Crohn's Disease (pMEDIC) will measure damage. The study enrolled children aged 6-18 with a new-onset or established diagnosis of CD. All patients had a MRE and a complete ileocolonoscopic evaluation, provided a stool sample for fecal calprotectin, and almost all had also a concurrent CRP measure.
Sites used a standardized MRE protocol agreed on by a Delphi process (Supplementary Appendix 1) . Explicit baseline, clinical, laboratory studies, treatments, and outcome data were recorded on electronic REDCap forms. Clinical disease activity was captured by the wPCDAI (remission <12.5 points, mild disease 12.5-40 points, moderate disease 40 <wPCDAI 57.5, and severe disease >57.5) 23 and physician (gastroenterologist) global assessment. Degree of endoscopic inflammation was captured by the SESCD (0-2 defined as mucosal healing, 3-6 mild disease, 7-15 moderate disease, and !16 severe disease). 12, 24, 25 RGA of the degree of MRE inflammation has been scored on a 100-mm visual analogue score (VAS), blinded to the clinical and endoscopic data, as a single global score for all disease segments (Supplementary Appendix 1). We could not find a prior reference of using RGA (100-mm VAS) to define transmural healing by MRE and thus we used the MaRIA score available in 103 (68%) of the cohort to determine the cutoff best defining RGA-associated remission. The MaRIA was scored by 2 independent radiologists who were blinded to the VAS score and was used here as the total score of all involved segments. The best cutoff of the 100-mm RGA indicating an inactive disease (ie, MaRIA score <7) was <19.5 mm with 85% sensitivity and 72% specificity (area under the receiver operating characteristic curve [AUROC], 0.84; 95% confidence interval [CI], 0.74-0.94), and this cutoff was thus used herein to define transmural remission. The sensitivity and specificity of the different VAS cutoffs are presented in Supplementary Table 1. In support of these findings, a prior published analysis of the ImageKids study validated the use of RGA scoring system for assessing inflammatory activity in pediatric CD 26 as well as others. [20] [21] [22] A total of 78 of the 151 readings had duplicate VAS scoring by 2 independent radiologists of both per segment and per the entire bowel, which allowed us to calculate the reliability of their scoring. The agreement was high: intraclass correlation coefficient of 0.81 (95% CI, 0.78-0.83; P < .0000001) for the per-segment assessment, and intraclass correlation coefficient of 0.76 (95% CI, 0.65-0.83; P < .0000001) for the entire bowel global assessment. When 2 VAS scores were available, the average of both was used for the reliability analysis.
We defined mucosal healing and transmural healing on a patient level and not per segment. A combination of mucosal healing together with transmural healing was defined as "deep healing."
Stool samples were obtained within a 2-week interval of colonoscopy (never during bowel cleansing), stored locally at À80 C and analyzed in a central laboratory (PhiCal Test, Calpro AS, Oslo, Norway; NovaTec Immunodiagnostica, Dietzenbach, GmBH, Germany).
Statistical Analysis
Continuous variables were compared using Student's t test or Wilcoxon rank sum test as appropriate for the data normality and Kruskal-Wallis for 3 or more independent groups. When multiple pairwise comparisons were performed, the Bonferroni-Holm correction was applied. Categorical variables were compared using chi-square or Fisher exact tests, as appropriate. Correlations were sought using Spearman coefficient. Receiver operating characteristic curves were plotted to compare the ability of continuous variables (eg, calprotectin and CRP) to predict mucosal healing, transmural healing, and deep healing and for exploring their optimal cutoff values while balancing sensitivity and specificity. All authors had access to the study data and reviewed and approved the final manuscript. All tests were 2 tailed and a P < .05 was considered statistically significant.
Results
A total of 243 children were enrolled of whom 151 provided a stool sample for calprotectin, had a complete ileocolonoscopy, and a concurrent MRE, and thus were included in this study (Table 1) . Of the 151 included children, 138 (91%) had a CRP value available, and 136 (90%) had all items required to calculate the wPCDAI (the main missing items were albumin and erythrocyte sedimentation rate [ESR]).
A total of 25 (17%) had low calprotectin <100 mg/g and of the 138 with CRP, 67 (49%) were normal (<5 mg/L). Out of these 138 children, 18 (13%) had both a normal CRP and low calprotectin, 4 (2.9%) had an Figure 1A) .
All 3 biomarkers (ie, calprotectin, CRP, and ESR) were highest in the combined transmural and mucosal inflammation group (Table 1) . Similarly, clinical remission rate was highest for the deep-healing group (15/19; 79%), followed by either the mucosal-healing without transmural-healing group (3/7; 43%) or the transmuralhealing without mucosal-healing group (12/31; 39%), and lowest for the group of both mucosal and transmural inflammation (9/79; 11%; P < .001) ( Table 1) . Collectively, these data show that 11%-43% of those with an active disease (mucosal and/or transmural) were in clinical remission.
Association of Mucosal Healing and Transmural Healing
Of all 151 included children, 21 (14%) had deep healing, 9 (6%) had mucosal healing without transmural healing, 38 (25%) had transmural healing without mucosal healing, and 83 (55%) had both mucosal and transmural inflammation. Among the subgroup of 113 children evaluated after commencing treatment (ie, excluding those at disease onset) 21 (19%) had deep healing, 6 (5.3%) had mucosal healing without transmural healing, 34 (30%) had transmural healing without mucosal healing, and 52 (46%) had both mucosal and transmural inflammation.
Predicting Mucosal Healing
SESCD had a good correlation with calprotectin (r ¼ 0.63; P < .001), whereas the correlation of SESCD with ESR and CRP was at most fair (r ¼ 0.42 and r ¼ 0.37, respectively; both P < .001). The median calprotectin in children with mucosal healing was lower than those without (60 mg/g [IQR, 10-260] vs 703 mg/g [442-1520], respectively; P < .001). In fact, calprotectin increased linearly with increased endoscopic disease severity ( Figure 1B) . The AUROC for calprotectin, CRP, and ESR to predict mucosal healing (regardless of the transmural status) was 0.93 (95% CI, 0.88-0.98), 0.81 (0.72-0.9), and 0.78 (0.68-0.88), respectively (Supplementary Figure 1) .
The best cutoff value of calprotectin to predict mucosal healing was <300 mg/g when balancing all diagnostic measures, and <100 mg/g when obtaining a specificity >90% at a cost of low sensitivity of 63% (Table 2) .
Predicting Transmural Healing
Calprotectin had a moderate correlation with RGA of MRE (r ¼ 0.47; P < .001), higher than the correlation of ESR and CRP with MRE (r ¼ 0.33 and r ¼ 0.37, respectively; both P < .001). The median calprotectin values in children with transmural healing were lower than those with an active transmural inflammation (282 mg/g [IQR, 72-733] vs 703 mg/g [IQR, 498-1581], respectively; P < .001).
Overall, calprotectin, CRP, and ESR also predicted transmural healing but to a lesser extent than mucosal healing, especially for calprotectin, which lost its superiority over the others (AUROC, 0.72 [95% CI, 0.63-0.81; P < .001], 0.7 [95% CI, 0.61-0.79; P < .001], 
Predicting Deep Healing
Median calprotectin and CRP levels in the 21 children with deep healing were 10 mg/g (IQR, , and 1 mg/L (IQR, 0.4-3.6), respectively, significantly lower than those who had either mucosal or transmural inflammation (Figure 2) . AUROC for calprotectin, CRP, and ESR to predict deep healing was 0.93 (95% CI, 0.89-0.98), 0.81 (95% CI, 0.71-0.9), and 0.77 (95% CI, 0.67-0.87), respectively (Supplementary Figure 3) . The best cutoff values of calprotectin to predict deep healing was <100 mg/g while balancing also positive predictive value and negative predictive value ( Table 2) . The best cutoff value of CRP to predict deep healing was <3 mg/L. CRP <0.5 mg/L obtained a specificity >90% at a cost of low sensitivity of 28% (Table 3) . We also examined combined cutoffs of calprotectin and CRP (Table 4) .
Discussion
In this study we have shown that one-third of patients have either mucosal healing with transmural inflammation or vice versa, supporting the notion that MRE is an important addition to colonoscopy in assessing CD. Calprotectin seems a more sensitive indicator of mucosal inflammation than of transmural inflammation but it is superior to CRP in predicting mucosal healing, transmural healing, and deep healing. As previously shown, 27 we found that calprotectin tended to be numerically lower in the small bowel.
The correlation between fecal calprotectin and endoscopic scores in CD varied from 0.42 to 0.73 in different studies, in the range of our findings.
27-30
Although a calprotectin cutoff of 300 mg/g was suitable for predicting mucosal healing in our study, a lower cutoff of 100 mg/g may be needed for predicting deep healing. Previous studies have suggested different cutoffs for predicting mucosal healing. A study of 122 adults found that a threshold of !50 mg/g predicted endoscopically active disease (SESCD !4) with 89% sensitivity and 72% specificity. 27 In a subanalysis of the STORI trial, calprotectin 150, 200, and 250 mg/g predicted CDEIS of 0 with sensitivity and specificity of 86%/39%, 89%/35%, and 89%/33%, respectively. 31 The sensitivity and specificity to predict CDEIS 3 were 77%/58%, 80%/53%, and 82%/53%, respectively, supporting the cutoff value of 150 mg/g. Other studies found cutoff values ranging between 50 and 250 mg/g with a sensitivity of 70%-94% and specificity of 58%-92%. 27, 32, 33 Studies on pediatric patients have also suggested cutoff values in this range with a sensitivity of 93%-100% and specificity of 80%-82%. 34, 35 Some studies have examined combined cutoffs of calprotectin and CRP for predicting mucosal healing. Bondjemah et al 36 showed that in adult active CD, calprotectin of 200 mg/g or CRP 5 mg/L can predict CDEIS 6 with 83% sensitivity and 71% specificity. When the study examined 355 patients in clinical remission, the combination of CRP 10 mg/L and calprotectin 200 mg/g predicted CDEIS 3 with 78% sensitivity and 58% specificity.
Studies have found that MRE remission is associated with improved long-term outcomes, such as surgery, hospital admissions, and therapy escalation. 37, 38 However, other recent studies indicated that transmural healing is achieved only in the minority of treated patients. 39, 40 There are limited data on the predictive value of calprotectin in determining transmural healing, especially in children. Studies have shown that calprotectin correlates with transmural inflammation measured by MRE, with a correlation coefficient range of 0.46-0.72. [41] [42] [43] Two studies arbitrarily chose a calprotectin cutoff >150 mg/g to associate calprotectin with inflammation documented by positron emission tomography-MRE 44 and MRE. 45 Cerillo et al 46 demonstrated that a calprotectin cutoff of 166.5 mg/g predicted transmural inflammation (ie, MaRIA score !7) with an AUROC of 0.914. We found a slightly lower cutoff of 100 mg/g but we predicted not merely transmural inflammation by MRE but also mucosal inflammation by colonoscopy (ie, deep healing).
In recent years the goal of therapy has shifted from clinical remission to endoscopic mucosal healing. However, progression to bowel damage may still occur in patients with mucosal healing because residual transmural inflammation often persists. It is plausible to assume that achieving transmural healing in addition to mucosal healing would be associated with a more favorable outcome but further studies are needed to determine the number needed to treat for achieving deep healing and which patients should qualify for intensified treatment in achieving this extended goal.
Our study is the first in pediatrics to explore the association between mucosal healing, transmural healing, and deep healing with calprotectin and CRP, but it is not without limitations. For defining transmural healing we used RGA of MRE, which is subjective and not widely validated. However, a cutoff of <20 mm for remission was benchmarked and validated internally by the MaRIA score available in a subset of our cohort. In this cohort we could not and did not aim for elucidating treatment effect in relation to deep healing, mainly because the disease duration varied and the indication for performing the endoscopic and radiologic evaluation was clinically based. Similarly, the long-term implication of achieving deep healing should be further assessed in future longitudinal studies. The strengths of our study include the large sample size; prospective data collection; the availability of MRE, ileocolonoscopy, and inflammatory biomarkers; and the integrative comprehensive analytic approach.
In summary, our study highlights the discrepancy between mucosal and transmural inflammation and the importance of evaluating the disease by both ileocolonoscopy and imaging. It also demonstrates that calprotectin level is driven primarily by mucosal inflammation but is still superior to CRP. Although a calprotectin cutoff <300 mg/g predicted mucosal healing, a lower cutoff of <100 mg/g may be more suitable to predict deep healing. Nonetheless, the accuracy of these values is only moderate and physicians should be familiar with the predictive values of each cutoff before incorporating them in the clinical decision making.
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Comments
It is anticipated all sites should be able to run option 1, the key requirement to include 1 b value 200.
Where possible, please try to use option 2 with 5 b values.
Given the time factor, it is not expected many sites will be able to run option 3 but please specify if you do.
FB may not be an option at some sites, requiring RT/ BH with increased acquisition time. If so, *limit coverage to lower poles kidneys to pubic symphysis in 1 station.
Reading
Each MRE was read 3 times by 3 independent radiologists highly experienced in pediatric inflammatory bowel disease (an on-site radiologist and 2 central radiologists [used for the calculation of the MaRIA], both using explicit case report form). The site radiologists were asked to measure the length of the involved segments and to score disease activity, stenosis, fistulizing, and damage using the VAS scale (considering thickness, T2, enhancement, DWI, mucosal changes, and mesenteric changes). A subset of the MREs (78 readings) were read again as "2nd site" reading by a forth radiologist (independent of the other 3). These readings were then averaged to 1 consensuses "site reading." The central readers measured quantitative values including T2, enhancement (T1 postgadolinium), wall thickness, length, referred to DWI, motility, ulcerations, edema, and global assessment of disease.
Supplementary Figure 3 . Receiver operating characteristic curve for predicting deep healing. 
